Sun Pharma approved to start COVID-19 treatment trial
Sun Pharmaceutical Industries Ltd. reported on Friday it received approval from Drugs Controller General of India to start a clinical trial for COVID-19 treatment with Nafamostat Mesilate.
Nafamostat, an anticoagulant used to treat acute pancreatitis, has been approved for human use in Japan and South Korea for over a decade.
Clinical trials of the drug have already started in Germany and Netherlands.
Get involved!
Comments